In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read More
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...
Read More
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) in metastatic prostate cancer. This study found that enzalutamide was associated with longer progression-free and overall survival compared to standard of care. Some background Enzalutamide is an anti-androgen medication....
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with castration-resistant prostate cancer (CRPC; cancer that progresses after hormonal therapy). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or...
Read MoreIn a nutshell This article investigated the safety and effectiveness of docetaxel (Taxotere)-based chemotherapy in combination with dexamethasone (Decadron) for the treatment of castration-resistant prostate cancer (CRPC). The authors concluded that this treatment combination is a safe and effective treatment option for...
Read More
In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...
Read More
In a nutshell This study examined stereotactic body radiotherapy (SBRT) as a treatment for advanced prostate cancer. This study concluded that SBRT may be effective in the treatment of these patients. Some background Oligometastatic prostate cancer is cancer that is no longer confined to the prostate gland. However, it has not yet become...
Read More
In a nutshell This study investigated the effectiveness of prostate radiotherapy (RT) in prostate cancer (PC). They found that prostate RT may improve survival in men with PC and fewer than 5 bone metastasis (cancer that has spread to the bones). Some background Prostate cancer (PC) is a common and treatable cancer in men. One common type...
Read More
In a nutshell This trial is examining the effectiveness of radical prostatectomy, in newly diagnosed advanced prostate cancer. The main outcome to be measured will be survival without the cancer worsening. This trial is recruiting in the United States. The details Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy (ADT) may...
Read More
